Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperprolactinaemia and female infertility.

G Godó

    Acta Medica Hungarica
    |January 1, 1984
    PubMed
    Summary

    Bromocriptine effectively treats hyperprolactinemia, a common cause of anovulation in infertile women. This medication suppresses prolactin secretion, normalizing menstrual cycles and improving fertility outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Significance of nuchal edema in fetuses of pregnant women under 35 years of age].

    Orvosi hetilap·2000
    Same author

    [Experience with gestodene-containing hormonal contraceptive].

    Orvosi hetilap·1998
    Same author

    [Simultaneous occurrence of bilateral extrauterine pregnancy and ovarian hyperstimulation syndrome following artificial heterologous insemination (differential diagnostic difficulties)].

    Orvosi hetilap·1990
    Same author

    Ovulation induction with pulsatile administration of human menopausal gonadotropin.

    Acta chirurgica Hungarica·1989
    Same author

    Variations in prolactin secretion in hyper- and normoprolactinaemia with or without galactorrhoea.

    Acta medica Hungarica·1989
    Same author

    [Ovulation induction in Kallman syndrome by intravenous pulsatory infusion of gonadotropin releasing hormone].

    Orvosi hetilap·1988

    Area of Science:

    • Reproductive Endocrinology
    • Clinical Pharmacology

    Background:

    • Hyperprolactinemia, characterized by elevated prolactin levels, frequently leads to ovulatory dysfunction, including anovulation, oligomenorrhea, and amenorrhea.
    • This hormonal imbalance is a significant factor contributing to infertility in women attending specialized clinics.
    • Elevated prolactin can also suppress ovarian estrogen (E2) production, further impacting reproductive health.

    Purpose of the Study:

    • To evaluate the clinical efficacy of bromocriptine in managing hyperprolactinemic women with infertility and menstrual irregularities.
    • To assess the impact of bromocriptine on prolactin secretion and its correlation with menstrual cycle abnormalities and fertility.

    Main Methods:

    • A clinical study involving 50 hyperprolactinemic and 30 normoprolactinemic women with infertility and ovulatory dysfunction.
    • Administration of bromocriptine to assess its effect on prolactin levels, menstrual cyclicity, and fertility.
    • Measurement of serum prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels.

    Main Results:

    • Bromocriptine demonstrated effectiveness in suppressing prolactin secretion across various underlying pathologies.
    • The study confirmed bromocriptine's efficacy in treating hyperprolactinemic states, leading to improved ovulatory function.
    • While prolactin levels did not strongly correlate with menstrual abnormalities or galactorrhea, subnormal E2 levels were observed, suggesting prolactin's inhibitory effect on ovarian estrogen production.

    Conclusions:

    • Bromocriptine is an effective therapeutic agent for hyperprolactinemia, addressing anovulation and infertility.
    • The drug normalizes prolactin levels irrespective of the cause, thereby restoring ovulatory cycles.
    • High prolactin levels (>100 ng/ml) may indicate a pituitary adenoma, warranting further investigation.

    Related Experiment Videos